INCA000585 not checked

Incyte Corporation

FollowEvery change as it happens, and a Monday email
Stage
 
Next date
Phase 2 trial completes
Trials
1 active
1 in total · 1 in the EU
Targets
—
None known yet

What this is

How it works
How it works isn't classified yet
How it’s given
“Tafasitamab will be administered intravenously at protocol defined timepoints.”In the company’s words, NCT07104565 on ClinicalTrials.gov
Tested for
Immune Thrombocytopenia
Main trialPhase 2
“This study will evaluate the safety and efficacy of tafasitamab in adult participants with primary autoimmune blood cell disorders.”In the company’s words, NCT07104565 on ClinicalTrials.gov

Other drugs for Immune Thrombocytopenia

All 32 drugs for Immune Thrombocytopenia

Coming up1

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials1

TrialPhaseCompletesWhat it tests
Phase 2Recruiting 23 Sep 2027 Study to Assess the Safety and Tolerability of Tafasitamab in Adult Participants With Primary Autoimmune Blood Cell Disorders
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026

Follow INCA000585

Following is part of Solo: you see every change to INCA000585 the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in